Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data
ChemMedChem2007Vol. 2(6), pp. 874–880
Citations Over TimeTop 1% of 2007 papers
Khalil Azzaoui, Jacques Hamon, Bernard Faller, Steven Whitebread, Edgar Jacoby, Andreas Bender, Jeremy L. Jenkins, László Urbán
Abstract
This study describes a method for mining and modeling binding data obtained from a large panel of targets (in vitro safety pharmacology) to distinguish differences between promiscuous and selective compounds. Two naïve Bayes models for promiscuity and selectivity were generated and validated on a test set as well as publicly available drug databases. The model shows a higher score (lower promiscuity) for marketed drugs than for compounds in early development or compounds that failed during clinical development. Such models can be used in triaging high-throughput screening data or for lead optimization.
Related Papers
- → Promiscuity and the evolutionary transition to complex societies(2010)372 cited
- → Bisexual Women, Non-Monogamy and Differentialist Anti-Promiscuity Discourses(2005)114 cited
- → Promiscuity and the evolution of sexual transmitted diseases(2003)6 cited
- → Mengatasi Pergaulan Bebas Dikalangan Masyarakat Ilmiah(2020)2 cited
- → THE DANGERS OF PROMISCUITY IN ADOLESCENCE(2022)